Drug therapies for ulcerative proctitis: Systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2157-2178

  Lie, Mitchell R K L ^a   Kanis, Shannon L ^a   Hansen, Bettina E ^a   Van Der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Therapy; Ulcerative colitis; Ulcerative proctitis

Indexed keywords

BETAMETHASONE; BUDESONIDE; ENEMA; HYDROCORTISONE; MESALAZINE; OLSALAZINE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; SUCRALFATE; SULFAPYRIDINE; ANTIINFLAMMATORY AGENT;

CORTICOSTEROID THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; FOAM; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RISK FACTOR; SUPPOSITORY; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT DURATION; ULCERATIVE PROCTITIS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MANAGEMENT;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MANAGEMENT; HUMANS; PROCTITIS;

EID: 84925621650     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000141     Document Type: Review

References (56)

1. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut. 1996;39:690-697.
2. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
3. Ayres RC, Gillen CD, Walmsley RS, et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8:555-558.
4. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95: 469-473.
5. Moum B, Ekbom A, Vatn MH, et al. Change in extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94:1564-1569.
6. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis. Scand J Gastroenterol. 1996;31:260-266.
7. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543-550.
8. Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10:731-736.
9. Cortot A, Maetz D, Degoutte E, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol. 2008;103:3106-3114.
10. Lennard-Jones JE, Baron JH, Connell AM, et al. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut. 1962;3:207-210.
11. Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther. 1998;12:707-715.
12. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005; 11:421-427.
13. Sutherland LR, Martin F. 5-aminosalicylic acid enemas in the maintenance of remission in distal ulcerative colitis and proctitis. Can J Gastroenterol. 1987;1:3-6.
14. Lindgren S, Löfberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and procitis. Scand J Gastroenterol. 2002;37:705-710.
15. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther. 1995;9:293-300.
16. Cominelli F, Zipser RD, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: a novel anti-inflammatory mechanism. Gastroenterology. 1992;96:A96.
17. Zingarelli B, Squadrito F, Graziani P, et al. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions. 1993;39:150.
18. Craven PA, Pfanstiel J, Saito R, et al. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology. 1987;92:1998.
19. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304.
20. Slade JD, Hepburn B. Prednisone-induced alterations of circulating human lymphocyte subsets. J Lab Clin Med. 1983;101:479.
21. Horst HJ, Flad HD. Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol. 1987;68:156.
22. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283.
23. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329.
24. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133.
25. Camussi G, Albano E, Tetta C, et al. The molecular action of tumor necrosis factor-alpha. Eur J Biochem. 1991;202:3-14.
26. Feagan BG, MacDonald JK. Oral 5-aminosailcylic acid for induction of remission in ulcerative colitis. Cochrane Database of Syst Rev. 2012;10: CD000544.
27. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Syst Rev. 2010;1:CD004115.
28. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Syst Rev. 2012;11:CD004118.
29. Ford AC, Bernstein CN, Khan JK, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590-599.
30. Timmer A, McDonald JWD, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Syst Rev. 2012;9:CD000478.
31. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671.
32. Handbook 2011Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from www.cochranehandbook. org. Accessed April 25, 2014.
33. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
34. Andus T, Kocjan A, Müser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16:1747-1756.
35. Ardizzone S, Petrillo M, Antonacci CM, et al. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis-a randomized singleblind comparative study. Aliment Pharmacol Ther. 1996;10:957-960.
36. Betamethasone 17-valerate, prednisolone 21-phosphate retention enemata in proctocolitis. Br Med J. 1971;3:84-86.
37. Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988;10:406-409.
38. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663-668.
39. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis. 1990;5:79-81.
40. Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: randomizedcontrolled clinical study comparing the efficacy and safety of a lowvolume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:1237-1249.
41. Farup PG, Hovde O, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. Scand J Gastroenterol. 1995;30:164-170.
42. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997;11:1053-1057.
43. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41:93-97.
44. Gross V, Bar-Meir S, Lavy A, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23:303-312.
45. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis; the ASCEND II trial. Am J Gastroenterol. 2005; 100:2478-2485.
46. Larnet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11: 625-630.
47. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14:1191-1198.
48. van Hees PAM, Bakker JH, van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study t determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21:632-635.
49. van Hogezand RA, van Hees PAM, van Gorp JPWM, et al. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988;2:33-40.
50. Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation- a placebo-controlled study. Aliment Pharmacol Ther. 2013;38: 264-273.
51. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-asa suppositories in active distal proctitis and measurement of extent of sread using 99mTc-labeled 5-asa suppositories. Dig Dis Sci. 1987;32:71S-75S.
52. d'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double blind placebo-controlled trial. Am J Gastroenterol. 1998;93:799-803.
53. d'Arienzo A, Panarese A, d'Armiento FP, et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoidits: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079-1082.
54. Hanauer SB, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa suppositories in remission maintenance in ulcerative proctitis). Am J Gastroenterol. 2000;95:1749-1754.
55. Nilsson A, Danielsson A, Löfberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol. 1995;90:381-387.
56. Travis SPL, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut. 1994;35:1282-1286.